Trump Administration Expands Coverage and Reduces Costs for Obesity Treatments Zepbound and Wegovy

President Trump has unveiled a deal to expand Medicare coverage and reduce prices for obesity medications Zepbound and Wegovy. The initiative aims to improve patient access to these popular treatments amid rising costs.

President Donald Trump announced a new agreement with pharmaceutical companies Eli Lilly and Novo Nordisk to broaden access and lower prices for their obesity drugs, Zepbound and Wegovy. These medications, classified as GLP-1 receptor agonists, have gained popularity but remain expensive, costing around USD 500 monthly for higher doses. Insurance coverage has been inconsistent, posing challenges for patients seeking these treatments.

Starting next year, Medicare will extend coverage for these obesity drugs, with some price reductions also being introduced for uninsured patients. The administration revealed that new pill versions of these treatments will be priced at USD 149 monthly if approved. This initiative is part of the Trump administration's ongoing efforts to address high drug prices and alleviate cost-of-living concerns among voters.

Medicare Coverage Expansion

Currently, Medicare covers these drugs for conditions like type 2 diabetes and cardiovascular disease but not solely for weight loss. The administration's plan will allow Medicare patients to access these treatments with USD 50 copays starting next year. Additionally, the TrumpRx program will enable individuals to purchase medications directly from manufacturers at reduced prices beginning in January.

The move to lower costs comes as the White House aims to show Trump's awareness of Americans' struggles with rising living expenses. Recent elections in New Jersey and Virginia highlighted economic concerns among voters, influencing outcomes in favour of Democratic candidates. The administration seeks to demonstrate its commitment to addressing these issues through initiatives like the drug pricing deal.

Obesity Treatments' Effectiveness

Obesity medications work by targeting hormones that regulate appetite and satiety. Clinical trials have shown significant weight loss results, with patients losing between 15% and 22% of their body weight. However, due to obesity being a chronic condition, continuous treatment is necessary to maintain weight loss.

Despite their effectiveness, the high cost of these drugs has made them inaccessible for many Americans. Dr. Leslie Golden, an obesity medicine specialist, noted that over 75% of her patients struggle to afford these treatments even with insurance coverage. Some patients face copayments as high as USD 150 for refills.

Doctors' Perspectives on Price Reductions

Dr. Angela Fitch expressed hope that the agreement between the White House and drugmakers could make obesity treatments more affordable. Fitch emphasised the need for better access to GLP-1 medications due to their proven effectiveness in managing obesity. Dr. Fatima Cody Stanford remains cautious about the potential impact on Medicare beneficiaries until more details are available.

Lilly has already reduced initial doses of Zepbound to USD 349 earlier this year. The possibility of covering these medications for the 30 million Medicare beneficiaries with obesity is seen as a positive step by healthcare professionals.

The Trump administration's deal aims to ensure Americans are not unfairly burdened with financing pharmaceutical innovations without adequate price concessions from drug makers. A senior official described it as a "belt and suspenders" approach, contrasting it with previous proposals deemed too favourable to the industry.

The administration also plans to offer lower prices for state and federally funded Medicaid programs. This initiative is part of broader efforts to address cost barriers associated with popular GLP-1 drugs amid growing demand and economic concerns nationwide.

With inputs from PTI